Previous 10 | Next 10 |
2023-08-03 16:31:33 ET Codexis press release ( NASDAQ: CDXS ): Q2 GAAP EPS of -$0.17 beats by $0.04 . Revenue of $21.32M (-44.5% Y/Y) in-line. 2023 Financial Guidance Codexis reiterated its 2023 financial guidance issued on July 20, 2023, as follows: Pr...
Company Recently Announced Enhanced Strategic Focus and Portfolio Prioritization Anticipate Demonstrating Gram-Scale Synthesis of ECO Synthesis™ Technology for RNAi Therapeutics Production by End of Year Projected Cash Runway to Mid-2026 Funds Important ECO Synthesis!...
REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the launch of a new mini documentary as part of an ongoing campaign in support of World Health Day. The film showcases the Company’s recently unveiled...
2023-07-20 18:32:06 ET Codexis ( NASDAQ: CDXS ) said that as part of its strategic focus, it will streamline operations, including laying off ~25% of its staff. The enzyme engineering company said it will prioritize the advancement and marketing of its Enzyme-Catalyzed Oligonu...
Organization Streamlined to Focus on Continued Advancement and Commercialization of ECO Synthesis™ Platform for RNAi Therapeutics Production Codexis Expects its Pharmaceutical Manufacturing Business to Return to Growth in 2024 Company Reiterates 2023 Product Revenue Guida...
2023-07-06 17:26:36 ET Gainers: Century Therapeutics ( NASDAQ: IPSC ) +8% . Codexis ( CDXS ) +5% . Alignment Healthcare ( ALHC ) +4% . Wag! Group ( PET ) +4% . Cadiz ( CDZI ) +3% . Losers: Renalytix ( RN...
2023-06-27 17:26:51 ET Gainers: Geospace Technologies ( GEOS ) +7% . AeroVironment ( AVAV ) +6% . Codexis ( CDXS ) +5% . Recursion Pharmaceuticals ( RXRX ) +3% . CECO Environmental ( CECO ) +3% . Losers: AST SpaceMo...
REDWOOD CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Healthcare Conference, being held June 7-9, 2023, in New York, New York. Management will participate in a fireside...
REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the unveiling of its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology, a proprietary new synthesis platform being developed for manufacturi...
2023-05-04 16:25:12 ET Codexis press release ( NASDAQ: CDXS ): Q1 Non-GAAP EPS of -$0.39. Revenue of $12.98M (-63.3% Y/Y) misses by $1.11M . CDXS reiterated its 2023 total revenue guidance range of $63 million to $68 million, excluding enzyme sales related to Paxlo...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...